Jaume Pons, PhD

Venture Partner

Dr. Pons is co-founder and CEO of ALX Oncology, a publicly traded immuno-oncology company that he led from inception in 2015. He is also co-founder and BOD member of Tallac therapeutics, a Venbio funded private company, that focuses on treatment of cancer using CPG-antibody conjugates.

Previously, as Senior Vice-President at Pfizer, he was Chief Scientific Officer and site head of Rinat (Pfizer) from 2007 to 2015, where he was responsible for portfolio delivery from idea to human proof of concept. During his tenure at Pfizer, Dr. Pons also served as Chief Technology Officer for Biotherapeutics, focusing on the evaluation and licensing of new platform technologies, member of Pfizer’s World R&D Leadership Team and member of the Portfolio Strategy Investment committee, the governance body that evaluates Pfizer’s clinical projects and guards the gateway to Phase 3 investment.

Dr. Pons is an inventor of Ajovy and has advanced thirteen additional protein therapeutics into human trials in multiple therapeutic areas

Dr. Pons is an inventor of Ajovy (anti CGRP antibody commercialized by Teva) and has advanced thirteen additional protein therapeutics into human trials in multiple therapeutic areas (including evorpacept, a phase 2 anti CD47 protein therapeutic for oncology in development by ALX Oncology). Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron.
Dr. Pons earned his Ph.D. in Molecular and Cell biology at the Institute of Fundamental Biology,
Barcelona.
He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.

Jaume Pons, PhD

Venture Partner

Dr. Pons is an inventor of Ajovy and has advanced thirteen additional protein therapeutics into human trials in multiple therapeutic areas

San Francisco office

Seattle office